Innovative Diagnostic Portfolio Rosetta Genomics offers a range of proprietary microRNA-based tests and molecular diagnostic assays, positioning it as a provider of advanced, gene expression profiling solutions suitable for hospitals, pathology labs, and research institutions seeking cutting-edge diagnostic tools.

Market Expansion Opportunities With services available in CAP-accredited and CLIA-certified laboratories located in Philadelphia and Lake Forest, there is potential to expand sales efforts into additional clinical laboratories and healthcare providers interested in genomic-based diagnostics for oncology and endocrinology.

Recent Acquisition Leverage Following its acquisition by Genoptix in 2017, Rosetta Genomics may have increased resources and distribution channels that can be tapped to accelerate sales of its microRNA tests and leverage existing customer relationships.

Technological Edge The company’s integration of bioinformatics with state-of-the-art laboratory processes provides a competitive advantage for selling comprehensive molecular testing solutions to diagnostic labs seeking innovative, validated testing options in cancer and thyroid diagnostics.

Growth Potential With annual revenues estimated between $10 million and $25 million and a focus on cancer and molecular diagnostics, there is considerable scope to target oncology clinics and hospitals interested in personalized treatment options and microRNA-based biomarker testing.